Autopsy report · NCT02514967

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study halted prematurely and will not resume. Subjects were seen until February 2017”

The sponsor’s own words in the registry.

Life of this trial

Registered 10 months before it started.
Ran for about 8 months before it stopped.
3 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Anthera Pharmaceuticals
Sponsor type: Industry
Conditions: Systemic Lupus Erythematosus
Interventions: Blisibimod; Placebo
Participants: 3
Sites: 3
Countries: Georgia

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.